6.130USD+0.49%Mkt Cap: 471.97M USDP/E: —Last update: 2026-05-26
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a de…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap471.97M USD
Enterprise Value595.13M USD
Revenue (TTM)1.00M USD
Gross Profit-1.95M USD
Net Income (TTM)-48.81M USD
Revenue/Share0.0120 USD
Last Price6.130 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.90
PEG—
EV/EBITDA-12.17
EV/Revenue595.13
P/S466.98
P/B4.68
EPS (TTM)-0.56
EPS (Forward)-0.51
52W Range
0.712071% of range8.330
52W High8.330 USD
52W Low0.7120 USD
Profitability
Gross Margin-195.10%
Oper. Margin-5258.30%
EBITDA Margin0.00%
Profit Margin-4880.90%
ROE-59.24%
ROA-53.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.88M USD
CapEx (TTM)71.00K USD
FCF Margin—
FCF Yield—
Net Debt-88.38M USD
Net Debt/EBITDA1.81
Balance Sheet
Debt/Equity0.03
Current Ratio22.07
Quick Ratio21.28
Book Value/Sh1.302 USD
Cash/Share0.8060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)12.50 USD
Target Range7.000 USD – 18.00 USD
# Analysts6
Ownership
Shares Out.76.68M
Float74.55M
Insiders5.09%
Institutions73.22%
Short Interest
Short Ratio3.2d
Short % Float1.93%
Short % Out.1.85%
Shares Short1.42M
Short (prev mo.)1.47M
Technical
SMA 506.696 (-8.5%)
SMA 2003.746 (+63.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)516.69K
Avg Vol (10d)667.54K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—